PT2684955T - Método para promover a angiogénese, a vascularização ou reparação de vasos ou para inibir a angiogénese de tumor - Google Patents

Método para promover a angiogénese, a vascularização ou reparação de vasos ou para inibir a angiogénese de tumor

Info

Publication number
PT2684955T
PT2684955T PT131791444T PT13179144T PT2684955T PT 2684955 T PT2684955 T PT 2684955T PT 131791444 T PT131791444 T PT 131791444T PT 13179144 T PT13179144 T PT 13179144T PT 2684955 T PT2684955 T PT 2684955T
Authority
PT
Portugal
Prior art keywords
angiogenesis
vascularisation
inhibiting tumour
vessel repair
promoting
Prior art date
Application number
PT131791444T
Other languages
English (en)
Portuguese (pt)
Inventor
Zeiher Andreas
Dimmeler Stefanie
Bonauer Angelika
Urbich Carmen
Original Assignee
T2Cure Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by T2Cure Gmbh filed Critical T2Cure Gmbh
Publication of PT2684955T publication Critical patent/PT2684955T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • C12N2310/113Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/50Methods for regulating/modulating their activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT131791444T 2007-10-30 2008-10-30 Método para promover a angiogénese, a vascularização ou reparação de vasos ou para inibir a angiogénese de tumor PT2684955T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102007052114A DE102007052114B4 (de) 2007-10-30 2007-10-30 Verfahren zur Modulation der Funktion, des Wachstums oder der Differenzierung einer Zelle

Publications (1)

Publication Number Publication Date
PT2684955T true PT2684955T (pt) 2017-12-13

Family

ID=40375407

Family Applications (2)

Application Number Title Priority Date Filing Date
PT131791444T PT2684955T (pt) 2007-10-30 2008-10-30 Método para promover a angiogénese, a vascularização ou reparação de vasos ou para inibir a angiogénese de tumor
PT88442736T PT2217704T (pt) 2007-10-30 2008-10-30 Método para promover a angiogénese, a vascularização ou reparação de vasos ou para inibir a angiogénese de tumor

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT88442736T PT2217704T (pt) 2007-10-30 2008-10-30 Método para promover a angiogénese, a vascularização ou reparação de vasos ou para inibir a angiogénese de tumor

Country Status (16)

Country Link
US (4) US8258113B2 (OSRAM)
EP (3) EP2684956B1 (OSRAM)
JP (4) JP5898843B2 (OSRAM)
CA (1) CA2704290C (OSRAM)
CY (2) CY1120360T1 (OSRAM)
DE (1) DE102007052114B4 (OSRAM)
DK (2) DK2217704T3 (OSRAM)
ES (2) ES2618203T3 (OSRAM)
HR (2) HRP20170346T1 (OSRAM)
HU (2) HUE031559T2 (OSRAM)
LT (2) LT2217704T (OSRAM)
NO (1) NO2684955T3 (OSRAM)
PL (2) PL2684955T3 (OSRAM)
PT (2) PT2684955T (OSRAM)
SI (2) SI2217704T1 (OSRAM)
WO (1) WO2009056116A1 (OSRAM)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030376A1 (it) 2003-07-31 2005-02-01 Univ Roma Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia.
US11660317B2 (en) 2004-11-08 2023-05-30 The Johns Hopkins University Compositions comprising cardiosphere-derived cells for use in cell therapy
DK2056845T3 (da) 2006-08-08 2017-11-27 Rheinische Friedrich-Wilhelms-Universität Bonn Struktur og anvendelse af 5'-phosphat-oligonukleotider
DE102007052114B4 (de) 2007-10-30 2011-01-05 T2Cure Gmbh Verfahren zur Modulation der Funktion, des Wachstums oder der Differenzierung einer Zelle
US9738680B2 (en) 2008-05-21 2017-08-22 Rheinische Friedrich-Wilhelms-Universität Bonn 5′ triphosphate oligonucleotide with blunt end and uses thereof
US9249392B2 (en) 2010-04-30 2016-02-02 Cedars-Sinai Medical Center Methods and compositions for maintaining genomic stability in cultured stem cells
US9845457B2 (en) 2010-04-30 2017-12-19 Cedars-Sinai Medical Center Maintenance of genomic stability in cultured stem cells
WO2012065024A1 (en) * 2010-11-11 2012-05-18 University Of Miami Compositions, cells, kits and methods for autologous stem cell therapy
EP2508530A1 (en) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Purification of triphosphorylated oligonucleotides using capture tags
EP2861238A4 (en) 2012-06-05 2016-03-16 Capricor Inc OPTIMIZED METHODS FOR GENERATING CARDIAC STEM CELLS FROM CARDIAC TISSUE AND THEIR USE IN CARDIAC THERAPY
CA2876180C (en) 2012-06-21 2019-11-19 MiRagen Therapeutics, Inc. Oligonucleotide-based inhibitors comprising locked nucleic acid motif
WO2014028493A2 (en) 2012-08-13 2014-02-20 Cedars-Sinai Medical Center Exosomes and micro-ribonucleic acids for tissue regeneration
EP2712870A1 (en) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Novel RIG-I ligands and methods for producing them
PL2759595T3 (pl) * 2013-01-24 2017-09-29 Pierre Fabre Médicament S.A.S. Kompozycja zawierająca kapsułkowany antagomir
EP2970968B1 (en) 2013-03-15 2018-01-10 Miragen Therapeutics, Inc. Bridged bicyclic nucleosides
US11253549B2 (en) 2014-05-23 2022-02-22 JangoBio, LLC Methods to rebalance the hypothalamic-pituitary-gonadal axis
US11439668B2 (en) 2014-05-23 2022-09-13 JangoBio, LLC Methods to differentiate stem cells into hormone-producing cells
JP6878274B2 (ja) 2014-10-03 2021-05-26 シーダーズ−サイナイ・メディカル・センターCedars−Sinai Medical Center 筋ジストロフィーの処置における心筋球由来細胞およびこのような細胞によって分泌されたエキソソーム
US20160122762A1 (en) * 2014-10-27 2016-05-05 University Of Iowa Research Foundation Methods of treating atherosclerosis
SG11201705907XA (en) * 2015-01-20 2017-08-30 Miragen Therapeutics Inc Mir-92 inhibitors and uses thereof
EP3402543B1 (en) 2016-01-11 2021-09-08 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction
WO2017210652A1 (en) 2016-06-03 2017-12-07 Cedars-Sinai Medical Center Cdc-derived exosomes for treatment of ventricular tachyarrythmias
CN107586784B (zh) * 2016-07-08 2020-08-25 田小利 一种分离的rnasek基因及其在制备抗血管衰老药物中的应用
US11541078B2 (en) 2016-09-20 2023-01-03 Cedars-Sinai Medical Center Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders
WO2018195210A1 (en) 2017-04-19 2018-10-25 Cedars-Sinai Medical Center Methods and compositions for treating skeletal muscular dystrophy
EP3727351A4 (en) 2017-12-20 2021-10-06 Cedars-Sinai Medical Center MANIPULATED EXTRACELLULAR VESICLES FOR ENHANCED RELEASE INTO TISSUE
US12146137B2 (en) 2018-02-05 2024-11-19 Cedars-Sinai Medical Center Methods for therapeutic use of exosomes and Y-RNAS
WO2019167995A1 (ja) * 2018-02-28 2019-09-06 国立大学法人東京医科歯科大学 虚血病変部位特異的な遺伝子治療法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1648914A4 (en) * 2003-07-31 2009-12-16 Regulus Therapeutics Inc OLIGOMERIC COMPOUNDS AND COMPOSITIONS USEFUL FOR MODULATING SMALL NON-CODING RNA
EP2290070B1 (en) * 2004-05-28 2015-03-25 Asuragen, Inc. Methods and compositions involving microRNA
US20090209621A1 (en) * 2005-06-03 2009-08-20 The Johns Hopkins University Compositions and methods for decreasing microrna expression for the treatment of neoplasia
ES2442890T3 (es) * 2006-07-13 2014-02-14 The Ohio State University Research Foundation Métodos y composiciones basados en micro-ARN para el diagnóstico y el tratamiento de enfermedades relacionadas con el colon
WO2008014008A2 (en) * 2006-07-28 2008-01-31 The Johns Hopkins University Compositions and methods for modulating angiogenesis
WO2008070082A2 (en) * 2006-12-04 2008-06-12 The Johns Hopkins University Stem-progenitor cell specific micro-ribonucleic acids and uses thereof
WO2009004632A2 (en) * 2007-07-05 2009-01-08 Yeda Research And Development Co. Ltd. Methods of identifying components of a biological pathway and use of said components in regulating diseases associated with altered cell proliferation
AU2008275877B2 (en) * 2007-07-18 2015-01-22 The Regents Of The University Of Colorado, A Body Corporate Differential expression of microRNAs in nonfailing versus failing human hearts
DE102007052114B4 (de) 2007-10-30 2011-01-05 T2Cure Gmbh Verfahren zur Modulation der Funktion, des Wachstums oder der Differenzierung einer Zelle

Also Published As

Publication number Publication date
US8258113B2 (en) 2012-09-04
US20160237433A1 (en) 2016-08-18
DE102007052114B4 (de) 2011-01-05
EP2217704B1 (de) 2016-12-07
LT2684955T (lt) 2017-12-27
US20100324118A1 (en) 2010-12-23
PL2684955T3 (pl) 2018-05-30
DK2684955T3 (en) 2017-12-18
US8912158B2 (en) 2014-12-16
ES2618203T3 (es) 2017-06-21
CY1120360T1 (el) 2019-07-10
US20120322856A1 (en) 2012-12-20
JP2016199565A (ja) 2016-12-01
US9279123B2 (en) 2016-03-08
EP2217704A1 (de) 2010-08-18
HRP20171874T1 (hr) 2018-01-12
EP2684955A1 (de) 2014-01-15
CA2704290A1 (en) 2009-05-07
NO2684955T3 (OSRAM) 2018-02-03
JP2014196317A (ja) 2014-10-16
US20150018407A1 (en) 2015-01-15
SI2217704T1 (sl) 2017-05-31
JP2018083817A (ja) 2018-05-31
PT2217704T (pt) 2017-03-15
SI2684955T1 (en) 2018-01-31
ES2651287T3 (es) 2018-01-25
WO2009056116A1 (de) 2009-05-07
EP2684955B1 (de) 2017-09-06
JP5898843B2 (ja) 2016-04-06
LT2217704T (lt) 2017-04-10
DE102007052114A1 (de) 2009-05-07
HUE031559T2 (hu) 2017-07-28
CA2704290C (en) 2018-05-15
EP2684956A1 (de) 2014-01-15
JP2011500858A (ja) 2011-01-06
HUE037494T2 (hu) 2018-08-28
DK2217704T3 (en) 2017-03-13
CY1120226T1 (el) 2018-12-12
HRP20170346T1 (hr) 2017-04-21
PL2217704T3 (pl) 2017-06-30
EP2684956B1 (de) 2017-08-23
US9862949B2 (en) 2018-01-09

Similar Documents

Publication Publication Date Title
HRP20171874T1 (hr) Postupak za poticanje angiogeneze, vaskularizacije ili obnavljanje krvnih žila ili za inhibiciju angiogeneze tumora
AP2012006304A0 (en) Hydraulic apparatus.
AP3883A (en) Refrigeration apparatus.
AP2011006035A0 (en) Fluid treatment apparatus.
EG26645A (en) Generate the power of the gyroglider control devices and the method used
AP2011006010A0 (en) Conveyor apparatus.
AP2012006347A0 (en) Conveyor apparatus.
AP2012006064A0 (en) Compounds and methods for treating influenza.
IL206972B (en) Fracture repair device
MX289002B (es) Metodo para la fabricacion de polimeros.
AP2012006052A0 (en) Improved method for synthesizing pirfenidone.
AP2010005473A0 (en) Solar stills.
ZA201107543B (en) Method for on-demand constraception
AP2012006277A0 (en) Method for treating androgen receptor positive cancers.
AP2011005857A0 (en) Tablets for combination therapy.
GB2477477A9 (en) Hob.
ZA201001584B (en) Quenching vessel
AP2012006099A0 (en) Torrefaction apparatus.
GB0915664D0 (en) Reaction method
SI2281801T1 (sl) Postopek za pridobivanje 3,3-diphenilpropilamina
AP2012006279A0 (en) Method for treating waste.
PL2446196T3 (pl) Sposób dostarczania ciepła
PL2484005T3 (pl) Sposób eksploatacji maszyny prądu stałego
AP2010005372A0 (en) Method for regulating agrobacterium-mediated transformation.
AP2011005932A0 (en) Pyrazinoisoquinoline Compounds.